[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

COVID-19 Impact on Global Kidney Cancer Therapeutics and Diagnostics Market Size, Status and Forecast 2020-2026

July 2020 | 95 pages | ID: C2484E9C73C3EN
QYResearch

US$ 3,900.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This report focuses on the global Kidney Cancer Therapeutics and Diagnostics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Kidney Cancer Therapeutics and Diagnostics development in North America, Europe and China.
The key players covered in this study
  • Bayer
  • Hoffmann La Roche
  • GlaxoSmithKline
  • Novartis
  • Pfizer
  • Abbott Laboratories
  • Amgen
  • Genentech
  • Cerulean Pharma
  • Seattle Genetics
Market segment by Type, the product can be split into
  • Cystoscopy
  • Biopsy
  • Intravenous Pyelogram
  • CT Scan
  • Kidney Ultrasound
  • Others
Market segment by Application, split into
  • Hospitals
  • Pharmaceutical Labs
  • Genomics Laboratories
  • Others
Market segment by Regions/Countries, this report covers
  • North America
  • Europe
  • China
The study objectives of this report are:
  • To analyze global Kidney Cancer Therapeutics and Diagnostics status, future forecast, growth opportunity, key market and key players.
  • To present the Kidney Cancer Therapeutics and Diagnostics development in North America, Europe and China.
  • To strategically profile the key players and comprehensively analyze their development plan and strategies.
  • To define, describe and forecast the market by type, market and key regions.
In this study, the years considered to estimate the market size of Kidney Cancer Therapeutics and Diagnostics are as follows:
  • History Year: 2015-2019
  • Base Year: 2019
  • Estimated Year: 2020
  • Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Kidney Cancer Therapeutics and Diagnostics Revenue
1.4 Market Analysis by Type
  1.4.1 Global Kidney Cancer Therapeutics and Diagnostics Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Cystoscopy
  1.4.3 Biopsy
  1.4.4 Intravenous Pyelogram
  1.4.5 CT Scan
  1.4.6 Kidney Ultrasound
  1.4.7 Others
1.5 Market by Application
  1.5.1 Global Kidney Cancer Therapeutics and Diagnostics Market Share by Application: 2020 VS 2026
  1.5.2 Hospitals
  1.5.3 Pharmaceutical Labs
  1.5.4 Genomics Laboratories
  1.5.5 Others
1.6 Coronavirus Disease 2019 (Covid-19): Kidney Cancer Therapeutics and Diagnostics Industry Impact
  1.6.1 How the Covid-19 is Affecting the Kidney Cancer Therapeutics and Diagnostics Industry
    1.6.1.1 Kidney Cancer Therapeutics and Diagnostics Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Kidney Cancer Therapeutics and Diagnostics Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Kidney Cancer Therapeutics and Diagnostics Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Kidney Cancer Therapeutics and Diagnostics Market Perspective (2015-2026)
2.2 Kidney Cancer Therapeutics and Diagnostics Growth Trends by Regions
  2.2.1 Kidney Cancer Therapeutics and Diagnostics Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Kidney Cancer Therapeutics and Diagnostics Historic Market Share by Regions (2015-2020)
  2.2.3 Kidney Cancer Therapeutics and Diagnostics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Kidney Cancer Therapeutics and Diagnostics Market Growth Strategy
  2.3.6 Primary Interviews with Key Kidney Cancer Therapeutics and Diagnostics Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Kidney Cancer Therapeutics and Diagnostics Players by Market Size
  3.1.1 Global Top Kidney Cancer Therapeutics and Diagnostics Players by Revenue (2015-2020)
  3.1.2 Global Kidney Cancer Therapeutics and Diagnostics Revenue Market Share by Players (2015-2020)
  3.1.3 Global Kidney Cancer Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Kidney Cancer Therapeutics and Diagnostics Market Concentration Ratio
  3.2.1 Global Kidney Cancer Therapeutics and Diagnostics Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Kidney Cancer Therapeutics and Diagnostics Revenue in 2019
3.3 Kidney Cancer Therapeutics and Diagnostics Key Players Head office and Area Served
3.4 Key Players Kidney Cancer Therapeutics and Diagnostics Product Solution and Service
3.5 Date of Enter into Kidney Cancer Therapeutics and Diagnostics Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Kidney Cancer Therapeutics and Diagnostics Historic Market Size by Type (2015-2020)
4.2 Global Kidney Cancer Therapeutics and Diagnostics Forecasted Market Size by Type (2021-2026)

5 KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Kidney Cancer Therapeutics and Diagnostics Market Size by Application (2015-2020)
5.2 Global Kidney Cancer Therapeutics and Diagnostics Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Kidney Cancer Therapeutics and Diagnostics Market Size (2015-2020)
6.2 Kidney Cancer Therapeutics and Diagnostics Key Players in North America (2019-2020)
6.3 North America Kidney Cancer Therapeutics and Diagnostics Market Size by Type (2015-2020)
6.4 North America Kidney Cancer Therapeutics and Diagnostics Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Kidney Cancer Therapeutics and Diagnostics Market Size (2015-2020)
7.2 Kidney Cancer Therapeutics and Diagnostics Key Players in Europe (2019-2020)
7.3 Europe Kidney Cancer Therapeutics and Diagnostics Market Size by Type (2015-2020)
7.4 Europe Kidney Cancer Therapeutics and Diagnostics Market Size by Application (2015-2020)

8 CHINA

8.1 China Kidney Cancer Therapeutics and Diagnostics Market Size (2015-2020)
8.2 Kidney Cancer Therapeutics and Diagnostics Key Players in China (2019-2020)
8.3 China Kidney Cancer Therapeutics and Diagnostics Market Size by Type (2015-2020)
8.4 China Kidney Cancer Therapeutics and Diagnostics Market Size by Application (2015-2020)
(2015-2020)
(2015-2020)

9 KEY PLAYERS PROFILES

9.1 Bayer
  9.1.1 Bayer Company Details
  9.1.2 Bayer Business Overview and Its Total Revenue
  9.1.3 Bayer Kidney Cancer Therapeutics and Diagnostics Introduction
  9.1.4 Bayer Revenue in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020))
  9.1.5 Bayer Recent Development
9.2 Hoffmann La Roche
  9.2.1 Hoffmann La Roche Company Details
  9.2.2 Hoffmann La Roche Business Overview and Its Total Revenue
  9.2.3 Hoffmann La Roche Kidney Cancer Therapeutics and Diagnostics Introduction
  9.2.4 Hoffmann La Roche Revenue in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020)
  9.2.5 Hoffmann La Roche Recent Development
9.3 GlaxoSmithKline
  9.3.1 GlaxoSmithKline Company Details
  9.3.2 GlaxoSmithKline Business Overview and Its Total Revenue
  9.3.3 GlaxoSmithKline Kidney Cancer Therapeutics and Diagnostics Introduction
  9.3.4 GlaxoSmithKline Revenue in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020)
  9.3.5 GlaxoSmithKline Recent Development
9.4 Novartis
  9.4.1 Novartis Company Details
  9.4.2 Novartis Business Overview and Its Total Revenue
  9.4.3 Novartis Kidney Cancer Therapeutics and Diagnostics Introduction
  9.4.4 Novartis Revenue in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020)
  9.4.5 Novartis Recent Development
9.5 Pfizer
  9.5.1 Pfizer Company Details
  9.5.2 Pfizer Business Overview and Its Total Revenue
  9.5.3 Pfizer Kidney Cancer Therapeutics and Diagnostics Introduction
  9.5.4 Pfizer Revenue in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020)
  9.5.5 Pfizer Recent Development
9.6 Abbott Laboratories
  9.6.1 Abbott Laboratories Company Details
  9.6.2 Abbott Laboratories Business Overview and Its Total Revenue
  9.6.3 Abbott Laboratories Kidney Cancer Therapeutics and Diagnostics Introduction
  9.6.4 Abbott Laboratories Revenue in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020)
  9.6.5 Abbott Laboratories Recent Development
9.7 Amgen
  9.7.1 Amgen Company Details
  9.7.2 Amgen Business Overview and Its Total Revenue
  9.7.3 Amgen Kidney Cancer Therapeutics and Diagnostics Introduction
  9.7.4 Amgen Revenue in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020)
  9.7.5 Amgen Recent Development
9.8 Genentech
  9.8.1 Genentech Company Details
  9.8.2 Genentech Business Overview and Its Total Revenue
  9.8.3 Genentech Kidney Cancer Therapeutics and Diagnostics Introduction
  9.8.4 Genentech Revenue in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020)
  9.8.5 Genentech Recent Development
9.9 Cerulean Pharma
  9.9.1 Cerulean Pharma Company Details
  9.9.2 Cerulean Pharma Business Overview and Its Total Revenue
  9.9.3 Cerulean Pharma Kidney Cancer Therapeutics and Diagnostics Introduction
  9.9.4 Cerulean Pharma Revenue in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020)
  9.9.5 Cerulean Pharma Recent Development
9.10 Seattle Genetics
  9.10.1 Seattle Genetics Company Details
  9.10.2 Seattle Genetics Business Overview and Its Total Revenue
  9.10.3 Seattle Genetics Kidney Cancer Therapeutics and Diagnostics Introduction
  9.10.4 Seattle Genetics Revenue in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020)
  9.10.5 Seattle Genetics Recent Development

10 ANALYST'S VIEWPOINTS/CONCLUSIONS

11 APPENDIX

11.1 Research Methodology
  11.1.1 Methodology/Research Approach
  11.1.2 Data Source
11.2 Disclaimer
11.3 Author Details
LIST OF TABLES

Table 1. Kidney Cancer Therapeutics and Diagnostics Key Market Segments
Table 2. Key Players Covered: Ranking by Kidney Cancer Therapeutics and Diagnostics Revenue
Table 3. Ranking of Global Top Kidney Cancer Therapeutics and Diagnostics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Kidney Cancer Therapeutics and Diagnostics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Cystoscopy
Table 6. Key Players of Biopsy
Table 7. Key Players of Intravenous Pyelogram
Table 8. Key Players of CT Scan
Table 9. Key Players of Kidney Ultrasound
Table 10. Key Players of Others
Table 11. COVID-19 Impact Global Market: (Four Kidney Cancer Therapeutics and Diagnostics Market Size Forecast Scenarios)
Table 12. Opportunities and Trends for Kidney Cancer Therapeutics and Diagnostics Players in the COVID-19 Landscape
Table 13. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 14. Key Regions/Countries Measures against Covid-19 Impact
Table 15. Proposal for Kidney Cancer Therapeutics and Diagnostics Players to Combat Covid-19 Impact
Table 16. Global Kidney Cancer Therapeutics and Diagnostics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 17. Global Kidney Cancer Therapeutics and Diagnostics Market Size by Regions (US$ Million): 2020 VS 2026
Table 18. Global Kidney Cancer Therapeutics and Diagnostics Market Size by Regions (2015-2020) (US$ Million)
Table 19. Global Kidney Cancer Therapeutics and Diagnostics Market Share by Regions (2015-2020)
Table 20. Global Kidney Cancer Therapeutics and Diagnostics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 21. Global Kidney Cancer Therapeutics and Diagnostics Market Share by Regions (2021-2026)
Table 22. Market Top Trends
Table 23. Key Drivers: Impact Analysis
Table 24. Key Challenges
Table 25. Kidney Cancer Therapeutics and Diagnostics Market Growth Strategy
Table 26. Main Points Interviewed from Key Kidney Cancer Therapeutics and Diagnostics Players
Table 27. Global Kidney Cancer Therapeutics and Diagnostics Revenue by Players (2015-2020) (Million US$)
Table 28. Global Kidney Cancer Therapeutics and Diagnostics Market Share by Players (2015-2020)
Table 29. Global Top Kidney Cancer Therapeutics and Diagnostics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Kidney Cancer Therapeutics and Diagnostics as of 2019)
Table 30. Global Kidney Cancer Therapeutics and Diagnostics by Players Market Concentration Ratio (CR5 and HHI)
Table 31. Key Players Headquarters and Area Served
Table 32. Key Players Kidney Cancer Therapeutics and Diagnostics Product Solution and Service
Table 33. Date of Enter into Kidney Cancer Therapeutics and Diagnostics Market
Table 34. Mergers & Acquisitions, Expansion Plans
Table 35. Global Kidney Cancer Therapeutics and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 36. Global Kidney Cancer Therapeutics and Diagnostics Market Size Share by Type (2015-2020)
Table 37. Global Kidney Cancer Therapeutics and Diagnostics Revenue Market Share by Type (2021-2026)
Table 38. Global Kidney Cancer Therapeutics and Diagnostics Market Size Share by Application (2015-2020)
Table 39. Global Kidney Cancer Therapeutics and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 40. Global Kidney Cancer Therapeutics and Diagnostics Market Size Share by Application (2021-2026)
Table 41. North America Key Players Kidney Cancer Therapeutics and Diagnostics Revenue (2019-2020) (Million US$)
Table 42. North America Key Players Kidney Cancer Therapeutics and Diagnostics Market Share (2019-2020)
Table 43. North America Kidney Cancer Therapeutics and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 44. North America Kidney Cancer Therapeutics and Diagnostics Market Share by Type (2015-2020)
Table 45. North America Kidney Cancer Therapeutics and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 46. North America Kidney Cancer Therapeutics and Diagnostics Market Share by Application (2015-2020)
Table 47. Europe Key Players Kidney Cancer Therapeutics and Diagnostics Revenue (2019-2020) (Million US$)
Table 48. Europe Key Players Kidney Cancer Therapeutics and Diagnostics Market Share (2019-2020)
Table 49. Europe Kidney Cancer Therapeutics and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 50. Europe Kidney Cancer Therapeutics and Diagnostics Market Share by Type (2015-2020)
Table 51. Europe Kidney Cancer Therapeutics and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 52. Europe Kidney Cancer Therapeutics and Diagnostics Market Share by Application (2015-2020)
Table 53. China Key Players Kidney Cancer Therapeutics and Diagnostics Revenue (2019-2020) (Million US$)
Table 54. China Key Players Kidney Cancer Therapeutics and Diagnostics Market Share (2019-2020)
Table 55. China Kidney Cancer Therapeutics and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 56. China Kidney Cancer Therapeutics and Diagnostics Market Share by Type (2015-2020)
Table 57. China Kidney Cancer Therapeutics and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 58. China Kidney Cancer Therapeutics and Diagnostics Market Share by Application (2015-2020)
Table 59. Bayer Company Details
Table 60. Bayer Business Overview
Table 61. Bayer Product
Table 62. Bayer Revenue in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 63. Bayer Recent Development
Table 64. Hoffmann La Roche Company Details
Table 65. Hoffmann La Roche Business Overview
Table 66. Hoffmann La Roche Product
Table 67. Hoffmann La Roche Revenue in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 68. Hoffmann La Roche Recent Development
Table 69. GlaxoSmithKline Company Details
Table 70. GlaxoSmithKline Business Overview
Table 71. GlaxoSmithKline Product
Table 72. GlaxoSmithKline Revenue in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 73. GlaxoSmithKline Recent Development
Table 74. Novartis Company Details
Table 75. Novartis Business Overview
Table 76. Novartis Product
Table 77. Novartis Revenue in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 78. Novartis Recent Development
Table 79. Pfizer Company Details
Table 80. Pfizer Business Overview
Table 81. Pfizer Product
Table 82. Pfizer Revenue in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 83. Pfizer Recent Development
Table 84. Abbott Laboratories Company Details
Table 85. Abbott Laboratories Business Overview
Table 86. Abbott Laboratories Product
Table 87. Abbott Laboratories Revenue in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 88. Abbott Laboratories Recent Development
Table 89. Amgen Company Details
Table 90. Amgen Business Overview
Table 91. Amgen Product
Table 92. Amgen Revenue in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 93. Amgen Recent Development
Table 94. Genentech Business Overview
Table 95. Genentech Product
Table 96. Genentech Company Details
Table 97. Genentech Revenue in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 98. Genentech Recent Development
Table 99. Cerulean Pharma Company Details
Table 100. Cerulean Pharma Business Overview
Table 101. Cerulean Pharma Product
Table 102. Cerulean Pharma Revenue in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 103. Cerulean Pharma Recent Development
Table 104. Seattle Genetics Company Details
Table 105. Seattle Genetics Business Overview
Table 106. Seattle Genetics Product
Table 107. Seattle Genetics Revenue in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 108. Seattle Genetics Recent Development
Table 109. Research Programs/Design for This Report
Table 110. Key Data Information from Secondary Sources
Table 111. Key Data Information from Primary Sources

LIST OF FIGURES

Figure 1. Global Kidney Cancer Therapeutics and Diagnostics Market Share by Type: 2020 VS 2026
Figure 2. Cystoscopy Features
Figure 3. Biopsy Features
Figure 4. Intravenous Pyelogram Features
Figure 5. CT Scan Features
Figure 6. Kidney Ultrasound Features
Figure 7. Others Features
Figure 8. Global Kidney Cancer Therapeutics and Diagnostics Market Share by Application: 2020 VS 2026
Figure 9. Hospitals Case Studies
Figure 10. Pharmaceutical Labs Case Studies
Figure 11. Genomics Laboratories Case Studies
Figure 12. Others Case Studies
Figure 13. Kidney Cancer Therapeutics and Diagnostics Report Years Considered
Figure 14. Global Kidney Cancer Therapeutics and Diagnostics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 15. Global Kidney Cancer Therapeutics and Diagnostics Market Share by Regions: 2020 VS 2026
Figure 16. Global Kidney Cancer Therapeutics and Diagnostics Market Share by Regions (2021-2026)
Figure 17. Porter's Five Forces Analysis
Figure 18. Global Kidney Cancer Therapeutics and Diagnostics Market Share by Players in 2019
Figure 19. Global Top Kidney Cancer Therapeutics and Diagnostics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Kidney Cancer Therapeutics and Diagnostics as of 2019
Figure 20. The Top 10 and 5 Players Market Share by Kidney Cancer Therapeutics and Diagnostics Revenue in 2019
Figure 21. North America Kidney Cancer Therapeutics and Diagnostics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Europe Kidney Cancer Therapeutics and Diagnostics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. China Kidney Cancer Therapeutics and Diagnostics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bayer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 25. Bayer Revenue Growth Rate in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020)
Figure 26. Hoffmann La Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Hoffmann La Roche Revenue Growth Rate in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020)
Figure 28. GlaxoSmithKline Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. GlaxoSmithKline Revenue Growth Rate in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020)
Figure 30. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Novartis Revenue Growth Rate in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020)
Figure 32. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Pfizer Revenue Growth Rate in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020)
Figure 34. Abbott Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Abbott Laboratories Revenue Growth Rate in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020)
Figure 36. Amgen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Amgen Revenue Growth Rate in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020)
Figure 38. Genentech Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Genentech Revenue Growth Rate in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020)
Figure 40. Cerulean Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Cerulean Pharma Revenue Growth Rate in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020)
Figure 42. Seattle Genetics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Seattle Genetics Revenue Growth Rate in Kidney Cancer Therapeutics and Diagnostics Business (2015-2020)
Figure 44. Bottom-up and Top-down Approaches for This Report
Figure 45. Data Triangulation
Figure 46. Key Executives Interviewed


More Publications